The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Human serum albumin, systemic inflammation, and cirrhosis
Open accessAbstract
Human serum albumin (HSA) is one of the most frequent treatments in patients with decompensated cirrhosis. Prevention of paracentesis-induced circulatory dysfunction, prevention of type-1 HRS associated with bacterial infections, and treatment of type-1 hepatorenal syndrome are the main indications. In these indications treatment with HSA is associated with improvement in survival. Albumin is a stable and very flexible molecule with a heart shape, 585 residues, and three domains of similar size, each one containing two sub-domains. Many of the physiological functions of HSA rely on its ability to bind an extremely wide range of endogenous and exogenous ligands, to increase their solubility in plasma, to transport them to specific tissues and organs, or to dispose of them when they are toxic. The chemical structure of albumin can be altered by some specific processes (oxidation, glycation) leading to rapid clearance and catabolism. An outstanding feature of HSA is its capacity to bind lipopolysaccharide and other bacterial products (lipoteichoic acid and peptidoglycan), reactive oxygen species, nitric oxide and other nitrogen reactive species, and prostaglandins. Binding to NO and prostaglandins are reversible, so they can be transferred to other molecules at different sites from their synthesis. Through these functions, HSA modulates the inflammatory reaction. Decompensated cirrhosis is a disease associated systemic inflammation, which plays an important role in the pathogenesis of organ or system dysfunction/failure. Although, the beneficial effects of HAS have been traditionally attributed to plasma volume expansion, they could also relate to its effects modulating systemic and organ inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Oxidative mechanisms in the toxicity of metal ions
Stohs, S. J., & Bagchi, D. (1995) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(94)00159-h · Cited by 4,219 · cited 6×
“Generation of ROS and RNS (superoxide, nitric oxide, hydrogen peroxide, hydroxyl radical, peroxynitrite, hypochlorous acid, nitrogen dioxide radical, hydroperoxide radical, and peroxyl radical) by neutrophils, macrophages, and endothelial cells, which represent the innate immune system, is the first line of defense ag…”
BackgroundInfluentialAtomic structure and chemistry of human serum albumin
He, X. M., & Carter, D. C. (1992) · Nature · doi:10.1038/358209a0 · Cited by 3,824
Protein Oxidation in Aging, Disease, and Oxidative Stress
Berlett, B. S., & Stadtman, E. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.33.20313 · Cited by 3,332
Moreau, R., Jalan, R., Gines, P., Pavesi, M., Angeli, P., Cordoba, J., Durand, F., Gustot, T., Saliba, F., Domenicali, M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.042 · Cited by 3,020
Self-citationStructural Basis of the Drug-binding Specificity of Human Serum Albumin
Ghuman, J., Zunszain, P. A., Petitpas, I., Bhattacharya, A. A., Otagiri, M., & Curry, S. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.075 · Cited by 1,941 · cited 1×
“Similarly to what is the case for LCFAs these molecules can bind to various sites in HSA and, although they tend to mainly interact with Sudlow’s sites I and II, this can vary depending on the relative concentration of competing ligands and on the allosteric effects discussed below [68].”
BackgroundHuman serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
(2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.004 · Cited by 1,725
Sort, P., Navasa, M., Arroyo, V., Aldeguer, X., Planas, R., Ruiz-del-Arbol, L., Castells, L., Vargas, V., Soriano, G., Guevara, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410603 · Cited by 1,654
Self-citationSchrier, R. W., Arroyo, V., Bernardi, M., Epstein, M., Henriksen, J. H., & Rodés, J. (1988) · Hepatology · doi:10.1002/hep.1840080532 · Cited by 1,623
Self-citation
Cited by
Lai, J. C., Tandon, P., Bernal, W., Tapper, E. B., Ekong, U., Dasarathy, S., & Carey, E. J. (2021) · Hepatology · doi:10.1002/hep.32049 · Cited by 742
Harnessing albumin as a carrier for cancer therapies
Hoogenboezem, E. N., & Duvall, C. L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.011 · Cited by 610
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Spada, A., Emami, J., Tuszynski, J. A., & Lavasanifar, A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00046 · Cited by 591
Rabbani, G., & Ahn, S. N. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.11.053 · Cited by 505
Cirrhosis-associated immune dysfunction
Albillos, A., Martin-Mateos, R., Van der Merwe, S., Wiest, R., Jalan, R., & Álvarez-Mon, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00520-7 · Cited by 447
Acute-on-chronic liver failure in cirrhosis
Arroyo, V., Moreau, R., Kamath, P. S., Jalan, R., Ginès, P., Nevens, F., Fernández, J., To, U., García-Tsao, G., & Schnabl, B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.41 · Cited by 434
Self-citationRecent trends in protein and peptide-based biomaterials for advanced drug delivery
Varanko, A., Saha, S., & Chilkoti, A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.008 · Cited by 369
Albumin in decompensated cirrhosis: new concepts and perspectives
Bernardi, M., Angeli, P., Claria, J., Moreau, R., Gines, P., Jalan, R., Caraceni, P., Fernandez, J., Gerbes, A. L., O'Brien, A. J., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318843 · Cited by 357
Self-citationManagement of the critically ill patient with cirrhosis: A multidisciplinary perspective
Nadim, M. K., Durand, F., Kellum, J. A., Levitsky, J., O’Leary, J. G., Karvellas, C. J., Bajaj, J. S., Davenport, A., Jalan, R., Angeli, P., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.019 · Cited by 297
Fernández, J., Clària, J., Amorós, A., Aguilar, F., Castro, M., Casulleras, M., Acevedo, J., Duran-Güell, M., Nuñez, L., Costa, M., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.03.021 · Cited by 274
Self-citationThe protein corona and its effects on nanoparticle-based drug delivery systems
Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265
Dysfunctional Immune Response in Acute-on-Chronic Liver Failure: It Takes Two to Tango
Martin-Mateos, R., Alvarez-Mon, M., & Albillos, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00973 · Cited by 116
Metadata
- Authors
- Arroyo, V., García-Martinez, R., & Salvatella, X.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 61
- Issue
- 2
- Pages
- 396-407
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2006957711
- Cited by
- 560
- References
- 121
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.